PMID: 66571Apr 9, 1977Paper

A specific orally active inhibitor of angiotensin-converting enzyme in man

R K FergusonD N McKinstry


An orally active inhibitor of the angiotensin-converting enzyme, SQ 14,225 (D-2-methyl-3-mercaptopropanoly-L-proline), was administered to fourteen normal male volunteers to evaluate its safety and efficacy in inhibiting pressor responses to exogenous angiotensin I. SQ 14,225 produced significant blockade within 15 min of oral administration. The magnitude and duration of inhibition were dose-related. After a dose of 20 mg, complete blockade was observed for more than 2 h and partial inhibition for over 4 h. There was no effect on pressor responses to angiotensin II. SQ 14,225 promises to provide a new approach to the diagnosis and treatment of disorders involving over-activity of the renin-angiotensin system.


Apr 1, 1991·Journal of Clinical Pharmacology·M A BaezD J Weidler
Jan 1, 1991·European Journal of Clinical Pharmacology·I F GowC R Edwards
Jan 1, 1984·European Journal of Clinical Pharmacology·M D SchallerH R Brunner
Jan 1, 1985·European Journal of Clinical Pharmacology·M D SchallerH R Brunner
Jan 1, 1983·European Journal of Clinical Pharmacology·J BiollazH R Brunner
Jan 1, 1981·European Journal of Clinical Pharmacology·P LijnenA Amery
Jan 1, 1985·European Journal of Clinical Pharmacology·R J FruncilloR K Ferguson
Mar 1, 1985·Naunyn-Schmiedeberg's Archives of Pharmacology·J P BussienP Hajdu
Jan 15, 1981·Klinische Wochenschrift·A StuderW Vetter
Oct 21, 1983·Pharmaceutisch Weekblad. Scientific Edition·P A Van ZwietenP B Timmermans
Apr 17, 2008·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Michael Bader, Detlev Ganten
Dec 1, 2011·Nanoscale Research Letters·Suguna Lakshmi MaduraiBoreddy Sr Reddy
Oct 1, 1987·American Heart Journal·B N Prichard, B Tomlinson
Nov 1, 1980·The American Journal of Medicine·H R Brunner, H Gavras
Jul 15, 1983·Clinica Chimica Acta; International Journal of Clinical Chemistry·F M DuncanC R Edwards
Dec 1, 1977·European Journal of Pharmacology·V S MurthyR R Vollmer
Sep 1, 1978·European Journal of Pharmacology·R R VollmerV S Murthy
Jun 1, 1981·Journal of Pharmacological Methods·I L NatoffA T Patel
Jan 1, 1986·The Journal of Emergency Medicine·M S Catapano, J A Marx
Oct 20, 1979·Lancet·A B Atkinson, J I Robertson
Feb 29, 2000·International Journal of Pharmaceutics·A O Nur, J S Zhang
Jan 1, 1983·Journal of the American College of Cardiology·E D Frohlich
Nov 1, 1983·Journal of the American College of Cardiology·M Packer
Mar 16, 1978·The New England Journal of Medicine·R ReE Haber
May 4, 1978·The New England Journal of Medicine·H GavrasD N McKinstry
Jun 21, 1979·The New England Journal of Medicine·J A Lopez-OvejeroJ H Laragh
Dec 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·R L SofferC Gloff
Jan 1, 1979·British Journal of Clinical Pharmacology·H R BrunnerI Gavras
Jan 1, 1979·British Journal of Clinical Pharmacology·Z P HorovitzR E Panasevich
Feb 1, 1988·Clinical and Experimental Pharmacology & Physiology·G K MoldenhauerT O Morgan
Mar 1, 1982·Archives of Disease in Childhood·W GriswoldS Mendoza
Feb 1, 1989·Archives of Disease in Childhood·C E Daman WillemsM J Dillon
Sep 23, 1978·British Medical Journal·M J VandenburgE J Rucinska
Nov 3, 1979·British Medical Journal·G A MacGregorJ C Jones

Related Concepts

Trending Feeds


Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Hereditary Sensory Autonomic Neuropathy

Hereditary Sensory Autonomic Neuropathies are a group of inherited neurodegenerative disorders characterized clinically by loss of sensation and autonomic dysfunction. Here is the latest research on these neuropathies.

Glut1 Deficiency

Glut1 deficiency, an autosomal dominant, genetic metabolic disorder associated with a deficiency of GLUT1, the protein that transports glucose across the blood brain barrier, is characterized by mental and motor developmental delays and infantile seizures. Follow the latest research on Glut1 deficiency with this feed.

Regulation of Vocal-Motor Plasticity

Dopaminergic projections to the basal ganglia and nucleus accumbens shape the learning and plasticity of motivated behaviors across species including the regulation of vocal-motor plasticity and performance in songbirds. Discover the latest research on the regulation of vocal-motor plasticity here.

Neural Activity: Imaging

Imaging of neural activity in vivo has developed rapidly recently with the advancement of fluorescence microscopy, including new applications using miniaturized microscopes (miniscopes). This feed follows the progress in this growing field.

Nodding Syndrome

Nodding Syndrome is a neurological and epileptiform disorder characterized by psychomotor, mental, and growth retardation. Discover the latest research on Nodding Syndrome here.

LRRK2 & Microtubules

Mutations in the LRRK2 gene are risk-factors for developing Parkinson’s disease (PD). LRRK2 mutations in PD have been shown to enhance its association with microtubules. Here is the latest research.